|
" Hirsutism. "
P Mauvais-Jarvis
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
739772
|
| Doc. No
|
:
|
b559703
|
| Main Entry
|
:
|
P Mauvais-Jarvis
|
| Title & Author
|
:
|
Hirsutism.\ P Mauvais-Jarvis
|
| Publication Statement
|
:
|
[Place of publication not identified]: Springer, 2012
|
| ISBN
|
:
|
3642815731
|
|
|
:
|
: 9783642815737
|
| Contents
|
:
|
A. Introduction.- B. Androgen Control of the Pilosebaceous Gland.- C. Androgen Production in Women.- I. Definition.- II. Androgen Biosynthetic Pathways.- III. Interconversion of Androgens.- IV. Plasma Levels and Blood Production Rates of Androgens.- V. Origin of Circulatory Androgens in Women.- 1. Testosterone.- 2. Androstenedione.- 3. Dehydroisoandrosterone and Dehydroisoandrosterone Sulphate.- 4. Dihydrotestosterone.- 5. Androstanediols.- VI. Control of Androgen Production in Women.- D. Androgen Transport in Blood.- I. Testosterone-Binding Globulin.- 1. Existence.- 2. Purification of TeBG.- 3. Characterization of TeBG in Serum.- 4. Steroid-Binding Parameters of TeBG.- II. Other Plasma Proteins Binding Androgens.- III. Regulation of TeBG Activity.- IV. Physiological Role of TeBG Binding of Testosterone.- 1. Relationship Between Testosterone Binding and Testosterone Metabolism.- 2. Control of the Oestrogen-Androgen Balance in Women.- 3. Selective Concentration of Active Molecules at the Target Cell Site.- E. Hepatic Metabolism.- F. Control of Plasma Level of Testosterone: Metabolic Clearance Rate.- G. Mechanism of Androgen Action in Human Skin.- I. Introduction.- II. 5?-Reduction of Testosterone into Dihydrotestosterone.- 1. In Vivo Studies.- 2. In Vitro Studies.- a) Biochemical Characterization.- b) Physiological Variations.- c) Control of Testosterone 5?-Reductase in Human Skin.- d) Pathological Models.- e) Studies with Cultured Skin Fibroblasts.- III. Dihydrotestosterone Formation from Other Androgen Precursors.- 1. Androstenedione.- 2. Dehydroisoandrosterone.- IV. Intracellular Metabolism of Dihydrotestosterone.- 1. Physiological Importance of 3?- and 3?-Androstanediols.- 2. Characterization of the 3-Ketoreductases.- V. Intracellular Retention of Dihydrotestosterone.- 1. Methodological Problems.- a) Cultured Fibroblasts.- b) Cell-Free Extracts.- 2. Characterization of the Androgen Receptor.- a) Physiochemical Properties.- b) Heat Lability.- c) Dissociation Constant.- d) Specificity.- 3. Physiological Variations.- 4. Control of Androgen Receptor Concentration.- 5. Pathological Variations.- VI. Conclusion.- H. Clinical and Biological Assessment of Hirsutism.- I. Clinical Assessment.- II. Hormonal Investigation of Hirsutism.- 1. Urinary 17-Ketosteroids.- a) Basal Conditions.- b) Tests of Ovarian Function.- c) Tests of Adrenal Function.- 2. Plasma Androgens.- a) Assays of Testosterone.- b) Assays of Androstenedione.- c) Dynamic Tests for Plasma Testosterone and Androstenedione.- d) Ovarian and Adrenal Vein Catheterization.- e) Dihydrotestosterone.- f) Other Steroids.- 3. Evaluation of Androstanediols.- 4. Conclusion.- I. Hirsutism of Adrenal Origin.- I. Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.- 1. Introduction.- 2. Frequency.- 3. Pathophysiology.- a) General Remarks.- b) Single or Multiple Enzymes.- 4. Androgen Production in 21-Hydroxylase Deficiency.- 5. Clinical and Hormonal Characteristics of Delayed Onset Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.- a) Hormonal Data from the Literature.- b) Personal Data.- c) Interpretation of Results.- 6. Identification of the Heterozygous State.- 7. Genetic Linkage Between 21-Hydroxylase Deficiency and the HLA Blood Group System.- 8. Treatment.- a) Corticosteroid Replacement.- b) Other Treatments.- II. Congenital Adrenal Hyperplasia Due to 11?-Hydroxylase Deficiency.- 1. Pathophysiology.- 2. Clinical Features.- 3. Hormonal Characteristics.- 4. Genetic Transmission.- 5. Treatment.- III. Virilizing Adrenal Tumours.- 1. Pathology.- a) Macroscopy.- b) Histology.- c) Malignant Criteria.- 2. Steroid Production.- a) Dehydroisoandrosterone.- b) Other Androgens.- 3. Clinical Aspects of Virilizing Adrenal Tumours.- a) Adult Females.- b) Prepubertal Females.- 4. Hormonal Findings.- a) Urinary Steroids.- b) Plasma Steroids.- c) Dynamic Tests.- 5. Physical Methods for Diagnosis of Virilizing Adrenal Tumours.- 6. Treatment.- a) Surgical.- b) Chemotherapy.- c) Benign Tumours.- J. Hirsutism of Ovarian Origin.- I. Polycystic Ovarian Syndrome.- 1. Theory of "Hypothalamic Masculinization".- 2. Two Types of Polycystic Ovaries.- 3. LH-RH Test in the Polycystic Ovarian Syndrome.- 4. Clomiphene Test.- 5. Oestradiol Test.- 6. Androgen Overproduction in Polycystic Ovarian Syndrome.- 7. Pathophysiology of Polycystic Ovarian Syndrome.- 8. Treatment.- 9. Conclusion.- II. Virilizing Ovarian Tumours.- 1. Pathological Classification.- a) Arrhenoblastoma.- b) Hilus Cell Tumours.- c) Lipid Cell Tumours.- d) Granulosa and Theca Cell Tumours.- e) Gonadoblastomas.- f) Functional Stroma Tumours.- g) Luteoma.- 2. Steroidogenesis.- a) Arrhenoblastoma.- b) Hilus Cell Tumours.- c) Luteoma.- 3. Clinical Features.- 4. Hormonal Investigations.- a) Assays in Basal Conditions.- b) Dynamic Tests.- c) Other Methods for Diagnosis.- 5. Differential Diagnosis.- 6. Prognosis.- 7. Treatment.- 8. Conclusion.- III. Ovarian Hyperthecosis.- K. Idiopathic Hirsutism.- I. Basis of Androgen Hypersensitivity.- II. Hypersensitivity Versus Androgen Overproduction.- III. Clinical and Biological Characteristics.- 1. Criteria for Estimation of Androgen Production.- 2. Criteria for Estimation of Peripheral Androgen Consumption.- 3. Personal Data.- a) In Vivo Studies.- b) In Vitro Studies.- e) Interpretation of Results.- IV. Treatment.- V. Conclusion.- L. Treatment of Hirsutism.- I. Introduction.- II. Methods.- 1. Oestrogens.- a) Mechanism of Action.- b) Clinical Use.- 2. Progesterone.- 3. Cyproterone Acetate.- a) Mechanism of Action.- b) Personal Results.- 4. Corticosteroids.- III. Conclusion.- References.
|
| LC Classification
|
:
|
RL431.P538 2012
|
| Added Entry
|
:
|
P Mauvais-Jarvis
|
| |